Anti-VEGF Peptide in Nanoparticle Hydrogel Could Reduce Eye Injections for Vision-Threatening Diseases
A PGS nanoparticle-hyaluronic acid hydrogel system sustained release of anti-VEGF HRH peptide for 3 months, inhibiting blood vessel growth and showing anti-neovascular effects in a mouse eye model.
Quick Facts
What This Study Found
HA-PGS NP@HRH achieved 42.54% drug release over 3 months, 55.19% inhibition of HUVEC viability, and suppression of neovascularization in an oxygen-induced retinopathy mouse model.
Key Numbers
How They Did This
PGS nanoparticle synthesis, hyaluronic acid hydrogel formulation, drug release kinetics, ARPE-19 and HUVEC cell viability/tube formation assays, and in vivo oxygen-induced retinopathy model in mice.
Why This Research Matters
Reducing eye injection frequency from monthly to quarterly or longer would dramatically improve quality of life for millions of patients with wet AMD and diabetic eye disease.
The Bigger Picture
Sustained peptide delivery for eye diseases represents a major unmet need. This nanoparticle-hydrogel approach could extend treatment intervals and improve patient outcomes.
What This Study Doesn't Tell Us
Mouse OIR model doesn't perfectly replicate human wet AMD. Long-term intraocular safety needs assessment. Three-month release may still require periodic injections.
Questions This Raises
- ?Could the release duration be extended beyond 3 months?
- ?How does this compare to existing sustained-release anti-VEGF approaches?
- ?Would the hydrogel remain stable and clear in the human vitreous?
Trust & Context
- Key Stat:
- 3-month sustained release The nanoparticle-hydrogel system maintained anti-VEGF peptide delivery over 3 months, potentially replacing monthly injections
- Evidence Grade:
- Preclinical study with thorough in vitro characterization and in vivo proof-of-concept. Promising but needs larger animal model validation.
- Study Age:
- Published in 2025.
- Original Title:
- Development of Nanoparticle-Hydrogel Drug Delivery System for Sustained Release of Anti-VEGF Peptide in Ocular Neovascularization Treatment.
- Published In:
- Macromolecular bioscience, 26(1), e00263 (2026)
- Authors:
- Durak, Saliha, Yetisgin, Abuzer Alp, Aciksari, Aysegul, Ceylan, Ramazan, Onder Tokuc, Ecem, Kutlu, Ozlem, Karabas, Veysel Levent, Cetinel, Sibel
- Database ID:
- RPEP-15129
Evidence Hierarchy
Frequently Asked Questions
Why do eye diseases need frequent injections?
Current anti-VEGF drugs break down quickly inside the eye, requiring monthly or bi-monthly injections. This sustained-release system keeps the drug active for 3 months from a single injection.
What is the HRH peptide?
HRH is an anti-VEGF peptide that blocks blood vessel growth factor receptors, preventing the abnormal blood vessel growth that causes vision loss in diseases like wet macular degeneration.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15129APA
Durak, Saliha; Yetisgin, Abuzer Alp; Aciksari, Aysegul; Ceylan, Ramazan; Onder Tokuc, Ecem; Kutlu, Ozlem; Karabas, Veysel Levent; Cetinel, Sibel. (2026). Development of Nanoparticle-Hydrogel Drug Delivery System for Sustained Release of Anti-VEGF Peptide in Ocular Neovascularization Treatment.. Macromolecular bioscience, 26(1), e00263. https://doi.org/10.1002/mabi.202500263
MLA
Durak, Saliha, et al. "Development of Nanoparticle-Hydrogel Drug Delivery System for Sustained Release of Anti-VEGF Peptide in Ocular Neovascularization Treatment.." Macromolecular bioscience, 2026. https://doi.org/10.1002/mabi.202500263
RethinkPeptides
RethinkPeptides Research Database. "Development of Nanoparticle-Hydrogel Drug Delivery System fo..." RPEP-15129. Retrieved from https://rethinkpeptides.com/research/durak-2026-development-of-nanoparticlehydrogel-drug
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.